-
Mashup Score: 25Changes in use of preventive medications after assessment of chest pain by coronary computed tomography angiography: A meta-analysis - 1 month(s) ago
In our meta-analysis, we found that patients experiencing chest pain undergoing CCTA receive a higher rate of preventive medications, as aspirin and statins, in comparison to those selecting cardiac stress testing. Furthermore, among individuals with plaque identified during the CCTA, there is a significantly elevated prescription rate for these medications when contrasted with patients showing no plaque in the exam. These findings emphasize the potential advantages of CCTA in guiding more effectiveness in preventive treatment strategies for individuals with chest pain.
Categories: General Medicine News, CardiologistsTweet
-
Mashup Score: 25Changes in use of preventive medications after assessment of chest pain by coronary computed tomography angiography: A meta-analysis - 2 month(s) ago
In our meta-analysis, we found that patients experiencing chest pain undergoing CCTA receive a higher rate of preventive medications, as aspirin and statins, in comparison to those selecting cardiac stress testing. Furthermore, among individuals with plaque identified during the CCTA, there is a significantly elevated prescription rate for these medications when contrasted with patients showing no plaque in the exam. These findings emphasize the potential advantages of CCTA in guiding more effectiveness in preventive treatment strategies for individuals with chest pain.
Categories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
UPDATED: Feb. 6 at 12:48 p.m. Centene’s top brass said Tuesday that the proposed Medicare Advantage rates for 2025 fall short of what’s needed. | Centene posted $45 million in profit for the fourth quarter of 2023, with its profitability for the full year growing notably compared to 2022.
Source: www.fiercehealthcare.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2
This meta-analysis report that GLP1-RA and SGLT2i reduced with a similar efficacy not only MACE as MI, but also cardiovascular mortality and all-cause mortality at a median 3-year follow-up. SGLT2i were more protective in HFH and WRF than GLP1RA. These new data highlight the efficacy of SGLT2i not o …
Source: pubmed.ncbi.nlm.nih.govCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3
AbstractAims. The relative safety and efficacy of de-escalation, extended duration (ED) (>12-months), and standard dual antiplatelet therapy for 12-months (D
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
AbstractAims. International guidelines recommend screening of first-degree relatives (FDR) of people with bicuspid aortic valves (BAVs). However, the prevalence
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis - 8 month(s) ago
AbstractAims. To summarise the totality of evidence validating the Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Du
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis - 8 month(s) ago
AbstractAims. Reduction of low-density lipoprotein cholesterol (LDL-C) decreases cardiovascular mortality and morbidity. Bempedoic acid represents a promising n
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 10Efficacy and Safety of Ticagrelor versus Clopidogrel in Dialysis Patients with Coronary Syndromes: A Systematic Review and Meta-Analysis - 8 month(s) ago
(1) Background: The optimal antiplatelet therapy for end-stage kidney disease (ESKD) patients on chronic dialysis presenting with acute or chronic coronary syndromes (ACS or CCS) remains uncertain. This meta-analysis aimed to compare the efficacy and safety endpoints of ticagrelor and clopidogrel in ESKD patients requiring dialysis and presenting with ACS or CCS. (2) Methods: Studies were included comparing ticagrelor and clopidogrel in ESKD patients on chronic dialysis with ACS or CCS. The primary composite efficacy outcome was a combination of all-cause and cardiovascular mortality, recurrent myocardial infarction or coronary revascularization, and ischemic or hemorrhagic stroke. The primary safety outcome was major and non-major bleeding events. (3) Results: Five observational studies met the eligibility criteria. The pooled analysis showed no significant difference in the primary composite efficacy outcome between ticagrelor and clopidogrel (p = 0.40). Similarly, the 2 groups had n
Source: www.mdpi.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4Cardiovascular events in patients treated with bempedoic acid versus placebo: systematic review and meta-analysis - 9 month(s) ago
AbstractAims. Reduction of low-density lipoprotein cholesterol (LDL-C) decreases cardiovascular mortality and morbidity. Bempedoic acid represents a promising n
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
Cardiovascular events in patients treated with bempedoic acid versus placebo: systematic review & meta-analysis https://t.co/dJnr7qBoln
-
Changes in use of preventive medications after assessment of chest pain by coronary computed tomography angiography: #MA https://t.co/vAhPyWiREh